{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:53:40Z","timestamp":1794020020468,"version":"4.8.0"},"reference-count":103,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.kint.2025.12.029","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T16:59:23Z","timestamp":1769101163000},"page":"661-670","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Primary hyperoxaluria(s): from trials to real-life data and pipeline therapies"],"prefix":"10.1016","volume":"109","author":[{"given":"Justine","family":"Bacchetta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Acquaviva-Bourdain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Abid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Laure","family":"Sellier Leclerc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Molin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3460-2507","authenticated-orcid":false,"given":"Sandrine","family":"Lemoine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2025.12.029_bib1","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1056\/NEJMra1301564","article-title":"Primary hyperoxaluria","volume":"369","author":"Cochat","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2025.12.029_bib2","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00467-022-05613-2","article-title":"Genetic assessment in primary hyperoxaluria: why it matters","volume":"38","author":"Mandrile","year":"2023","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2025.12.029_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/jimd.12817","article-title":"Human glyoxylate metabolism revisited: new insights pointing to multi-organ involvement with implications for siRNA-based therapies in primary hyperoxaluria","volume":"48","author":"Wanders","year":"2025","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.kint.2025.12.029_bib4","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1016\/j.ekir.2023.07.025","article-title":"Determinants of kidney failure in primary hyperoxaluria type 1: findings of the European Hyperoxaluria Consortium","volume":"8","author":"Metry","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2025.12.029_bib5","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.kint.2019.08.018","article-title":"Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up","volume":"96","author":"Garrelfs","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.12.029_bib6","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.kint.2021.03.031","article-title":"A report from the European Hyperoxaluria Consortium (OxalEurope) Registry on a large cohort of patients with primary hyperoxaluria type 3","volume":"100","author":"Martin-Higueras","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.12.029_bib7","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00467-023-06074-x","article-title":"Natural history of urine and plasma oxalate in children with primary hyperoxaluria type 1","volume":"39","author":"Sas","year":"2024","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2025.12.029_bib8","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/ndt\/gfab027","article-title":"Clinical characterization of primary hyperoxaluria type 3 in comparison with types 1 and 2","volume":"37","author":"Singh","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.12.029_bib9","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1053\/j.ajkd.2022.01.428","article-title":"Estimated GFR slope across CKD stages in primary hyperoxaluria type 1","volume":"80","author":"Singh","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2025.12.029_bib10","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s41581-022-00661-1","article-title":"Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope","volume":"19","author":"Groothoff","year":"2023","journal-title":"Nat Rev Nephrol"},{"issue":"87","key":"10.1016\/j.kint.2025.12.029_bib11","first-page":"138","article-title":"Urine oxalate excretion and CKD stage in patients with primary hyperoxaluria type 1","volume":"2026","author":"Vaughan","year":"2025","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2025.12.029_bib12","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.ekir.2022.04.012","article-title":"Improved outcome of infantile oxalosis over time in Europe: data from the OxalEurope Registry","volume":"7","author":"Deesker","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2025.12.029_bib13","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.1111\/ajt.16762","article-title":"Primary hyperoxaluria diagnosed after kidney transplant: a review of the literature and case report of aggressive renal replacement therapy and lumasiran to prevent allograft loss","volume":"21","author":"Stone","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2025.12.029_bib14","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1136\/jmedgenet-2021-108256","article-title":"Dominant negative mutation in oxalate transporter SLC26A6 associated with enteric hyperoxaluria and nephrolithiasis","volume":"59","author":"Corni\u00e8re","year":"2022","journal-title":"J Med Genet"},{"key":"10.1016\/j.kint.2025.12.029_bib15","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.arcped.2022.02.008","article-title":"Vitamin D and calcium intakes in general pediatric populations: a French expert consensus paper","volume":"29","author":"Bacchetta","year":"2022","journal-title":"Arch Pediatr"},{"key":"10.1016\/j.kint.2025.12.029_bib16","article-title":"Acute kidney injury from biopsy-proven renal oxalosis from excessive intake of vitamin C leading to end-stage kidney disease","volume":"14","author":"Williams","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.kint.2025.12.029_bib17","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1093\/ckj\/sfab233","article-title":"Primary hyperoxaluria type 1: time for prime time?","volume":"15","author":"Bacchetta","year":"2022","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2025.12.029_bib18","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/oxfordjournals.qjmed.a067914","article-title":"Primary hyperoxaluria (type I): attempted treatment by combined hepatic and renal transplantation","volume":"57","author":"Watts","year":"1985","journal-title":"Q J Med"},{"key":"10.1016\/j.kint.2025.12.029_bib19","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S0140-6736(89)92423-9","article-title":"Liver transplantation in primary hyperoxaluria type 1","volume":"1","author":"Cochat","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2025.12.029_bib20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/0014-5793(86)80563-4","article-title":"Peroxisomal alanine: glyoxylate aminotransferase deficiency in primary hyperoxaluria type I","volume":"201","author":"Danpure","year":"1986","journal-title":"FEBS Lett"},{"key":"10.1016\/j.kint.2025.12.029_bib21","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1093\/ndt\/gfs078","article-title":"Primary hyperoxaluria type 1: indications for screening and guidance for diagnosis and treatment","volume":"27","author":"Cochat","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.12.029_bib22","doi-asserted-by":"crossref","first-page":"18249","DOI":"10.1073\/pnas.0607218103","article-title":"Alanine-glyoxylate aminotransferase-deficient mice, a model for primary hyperoxaluria that responds to adenoviral gene transfer","volume":"103","author":"Salido","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2025.12.029_bib23","first-page":"570","article-title":"FDA approves patisiran to treat hereditary transthyretin amyloidosis","volume":"14","author":"Wood","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.kint.2025.12.029_bib24","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/mt.2016.4","article-title":"Inhibition of glycolate oxidase with dicer-substrate siRNA reduces calcium oxalate deposition in a mouse model of primary hyperoxaluria type 1","volume":"24","author":"Dutta","year":"2016","journal-title":"Mol Ther"},{"key":"10.1016\/j.kint.2025.12.029_bib25","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.54363","article-title":"Characterising a healthy adult with a rare HAO1 knockout to support a therapeutic strategy for primary hyperoxaluria","volume":"9","author":"McGregor","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.kint.2025.12.029_bib26","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/jmedgenet-2014-102529","article-title":"Mutations in HAO1 encoding glycolate oxidase cause isolated glycolic aciduria","volume":"51","author":"Frishberg","year":"2014","journal-title":"J Med Genet"},{"key":"10.1016\/j.kint.2025.12.029_bib27","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10545-017-0105-8","article-title":"Correlation between the molecular effects of mutations at the dimer interface of alanine\u2013glyoxylate aminotransferase leading to primary hyperoxaluria type I and the cellular response to vitamin B6","volume":"41","author":"Dindo","year":"2018","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.kint.2025.12.029_bib28","doi-asserted-by":"crossref","first-page":"458","DOI":"10.2215\/CJN.07430711","article-title":"Characteristics and outcomes of children with primary oxalosis requiring renal replacement therapy","volume":"7","author":"Harambat","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.12.029_bib29","article-title":"RNA interference medication and transplantation procedures in patients with primary hyperoxaluria type 1 (PH1)","author":"Martin-Higueras","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.12.029_bib30","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","article-title":"Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1","volume":"384","author":"Garrelfs","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2025.12.029_bib31","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00467-022-05684-1","article-title":"Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial","volume":"38","author":"Hayes","year":"2023","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2025.12.029_bib32","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/j.ekir.2024.04.048","article-title":"Efficacy and safety of lumasiran in patients with primary hyperoxaluria type 1: results from a phase III clinical trial","volume":"9","author":"Saland","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2025.12.029_bib33","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1053\/j.ajkd.2022.05.012","article-title":"Lumasiran for advanced primary hyperoxaluria type 1: phase 3 ILLUMINATE-C trial","volume":"81","author":"Michael","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2025.12.029_bib34","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1053\/j.ajkd.2025.01.016","article-title":"Efficacy and safety of lumasiran for advanced primary hyperoxaluria type 1: 24-month follow-up of the Phase 3 ILLUMINATE-C trial","volume":"86","author":"Sellier-Leclerc","year":"2025","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2025.12.029_bib35","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.kint.2021.08.015","article-title":"Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria","volume":"101","author":"Hoppe","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.12.029_bib36","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.kint.2022.07.025","article-title":"PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2","volume":"103","author":"Baum","year":"2023","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.12.029_bib37","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.ekir.2024.02.1439","article-title":"Nedosiran safety and efficacy in PH1: interim analysis of PHYOX3","volume":"9","author":"Groothoff","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2025.12.029_bib38","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.ekir.2025.03.031","article-title":"PHYOX3: nedosiran long-term safety and efficacy in patients with primary hyperoxaluria type 1","volume":"10","author":"Lieske","year":"2025","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2025.12.029_bib39","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1007\/s00467-025-06675-8","article-title":"Nedosiran in pediatric patients with PH1 and relatively preserved kidney function, a phase 2 study (PHYOX8)","volume":"40","author":"Sas","year":"2025","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2025.12.029_bib99","unstructured":"Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD (PHYOX7). ClinicalTrials.gov idenifier: NCT04580420. Updated December 24, 2025. Accessed February 4, 2026. https:\/\/clinicaltrials.gov\/study\/NCT04580420"},{"key":"10.1016\/j.kint.2025.12.029_bib40","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1007\/s00467-024-06328-2","article-title":"Diagnosis and management of primary hyperoxalurias: best practices","volume":"39","author":"Michael","year":"2024","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2025.12.029_bib41","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfae383","article-title":"The efficacy and safety of RNA interference for the treatment of primary hyperoxaluria: a systematic review and meta-analysis","volume":"18","author":"Yu","year":"2025","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2025.12.029_bib42","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.ekir.2024.12.033","article-title":"Real-life data of 2-year lumasiran use in the DAILY-LUMA cohort","volume":"10","author":"Sellier-Leclerc","year":"2025","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2025.12.029_bib43","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ekir.2023.10.004","article-title":"Multicenter long-term real world data on treatment with lumasiran in patients with primary hyperoxaluria type 1","volume":"9","author":"Martin-Higueras","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2025.12.029_bib44","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s00467-025-06665-w","article-title":"Variable treatment response to lumasiran in pediatric patients with primary hyperoxaluria type 1","volume":"40","author":"Saffe","year":"2025","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2025.12.029_bib45","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3343\/alm.2023.0178","article-title":"Primary hyperoxaluria screening and monitoring: quantitative measurement of plasma oxalate by gas chromatography-mass spectrometry with high sensitivity","volume":"44","author":"Yazdanpanah","year":"2024","journal-title":"Ann Lab Med"},{"key":"10.1016\/j.kint.2025.12.029_bib46","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1681\/ASN.2020121793","article-title":"High oxalate concentrations correlate with increased risk for sudden cardiac death in dialysis patients","volume":"32","author":"Pfau","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.12.029_bib47","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1684\/ndt.2025.108","article-title":"Fine-tuning circulating oxalate levels to improve transplant strategies in primary hyperoxaluria: what is the ideal threshold in pediatrics?","volume":"21","author":"Makosso Afiavi","year":"2025","journal-title":"Nephrol Ther"},{"key":"10.1016\/j.kint.2025.12.029_bib48","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s00467-016-3324-6","article-title":"Pediatric combined liver-kidney transplantation: a single-center experience of 18 cases","volume":"31","author":"Duclaux-Loras","year":"2016","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2025.12.029_bib49","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/ndt\/gfac295","article-title":"Isolated kidney transplantation under lumasiran therapy in primary hyperoxaluria type 1: a report of five cases","volume":"38","author":"Sellier-Leclerc","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.12.029_bib50","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.kint.2021.10.022","article-title":"Early post-transplant recurrence of oxalate nephropathy in a patient with primary hyperoxaluria type 1, despite pretransplant lumasiran therapy","volume":"101","author":"Joher","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.12.029_bib51","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1056\/NEJMc2312941","article-title":"Lumasiran, isolated kidney transplantation, and continued vigilance","volume":"390","author":"Bacchetta","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2025.12.029_bib52","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1159\/000531053","article-title":"A case report of kidney-only transplantation in primary hyperoxaluria type 1: a novel approach with the use of nedosiran","volume":"13","author":"Breeggemann","year":"2023","journal-title":"Case Rep Nephrol Dial"},{"key":"10.1016\/j.kint.2025.12.029_bib53","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.kint.2023.04.009","article-title":"Successful kidney-alone transplantation in a patient with PH1 on combination RNA-interference therapy","volume":"104","author":"Metry","year":"2023","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.12.029_bib54","first-page":"141","article-title":"Plasma glycolate levels contribute to drive the decision of isolated kidney transplantation in dialyzed patients with end-stage kidney disease due to primary hyperoxaluria type 1 treated with lumasiran: a case report","volume":"15","author":"Moretti","year":"2025","journal-title":"Case Rep Nephrol Dial"},{"key":"10.1016\/j.kint.2025.12.029_bib55","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.kint.2023.05.015","article-title":"Tolvaptan to prevent calcium oxalate crystal deposition in the kidney allograft after kidney transplantation for primary hyperoxaluria","volume":"104","author":"Stehl\u00e9","year":"2023","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.12.029_bib56","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1681\/ASN.2016020132","article-title":"Oxalobacter formigenes-derived bioactive factors stimulate oxalate transport by intestinal epithelial cells","volume":"28","author":"Arvans","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.12.029_bib57","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4103\/iju.iju_359_24","article-title":"Efficacy and safety of Oxalobacter formigenes in patients with primary hyperoxaluria: a systematic review and meta-analysis of randomized controlled trials","volume":"41","author":"Khan","year":"2025","journal-title":"Indian J Urol"},{"key":"10.1016\/j.kint.2025.12.029_bib58","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/ndt\/gfaa135","article-title":"Effects of Oxalobacter formigenes in subjects with primary hyperoxaluria type 1 and end-stage renal disease: a phase II study","volume":"36","author":"Hoppe","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.12.029_bib59","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/j.ekir.2025.02.004","article-title":"Inducing Oxalobacter formigenes colonization reduces urinary oxalate in healthy adults","volume":"10","author":"Fargue","year":"2025","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2025.12.029_bib60","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s00240-023-01453-3","article-title":"Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4)","volume":"51","author":"Goldfarb","year":"2023","journal-title":"Urolithiasis"},{"key":"10.1016\/j.kint.2025.12.029_bib61","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1093\/ndt\/gfaf035","article-title":"Global access to management of primary hyperoxaluria: a survey on behalf of OxalEurope, G&K working group of the ERA, and ESPN","volume":"40","author":"Deesker","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.12.029_bib62","doi-asserted-by":"crossref","first-page":"5454","DOI":"10.1038\/s41467-018-07827-1","article-title":"CRISPR\/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I","volume":"9","author":"Zabaleta","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.kint.2025.12.029_bib63","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.omtm.2022.03.006","article-title":"In vivo CRISPR-Cas9 inhibition of hepatic LDH as treatment of primary hyperoxaluria","volume":"25","author":"Martinez-Turrillas","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.kint.2025.12.029_bib64","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1089\/crispr.2024.0100","article-title":"Initial characterization of 12 new subtypes and variants of type V CRISPR systems","volume":"8","author":"Tordoff","year":"2025","journal-title":"CRISPR J"},{"key":"10.1016\/j.kint.2025.12.029_bib100","unstructured":"Phase 1\/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine). ClinicalTrials.gov identifier: NCT06839235. Updated December 24, 2025. Accessed February 4, 2026. https:\/\/clinicaltrials.gov\/study\/NCT06839235"},{"key":"10.1016\/j.kint.2025.12.029_bib101","unstructured":"Clinical Exploration Study of YOLT-203 in the Treatment of Type 1 Primary Hyperoxaluria (PH1). ClinicalTrials.gov identifier: NCT06511349. Updated May 16, 2025. Accessed February 4, 2026. https:\/\/clinicaltrials.gov\/study\/NCT06511349"},{"key":"10.1016\/j.kint.2025.12.029_bib65","article-title":"Preclinical evaluation of AGT mRNA replacement therapy for primary hyperoxaluria type I disease","volume":"11","author":"Yang","year":"2025","journal-title":"Sci Adv"},{"key":"10.1016\/j.kint.2025.12.029_bib66","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1172\/JCI99822","article-title":"Stiripentol protects against calcium oxalate nephrolithiasis and ethylene glycol poisoning","volume":"129","author":"Le Dudal","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.kint.2025.12.029_bib67","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s00467-020-04585-5","article-title":"Stiripentol fails to lower plasma oxalate in a dialysis-dependent PH1 patient","volume":"35","author":"Kempf","year":"2020","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2025.12.029_bib68","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.ajkd.2022.12.005","article-title":"Stiripentol and lumasiran as a rescue therapy for oxalate nephropathy recurrence after kidney transplantation in an adult patient with primary hyperoxaluria type 1","volume":"82","author":"Lombardi","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2025.12.029_bib69","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/ckj\/sfaa068","article-title":"Is stiripentol truly effective for treating primary hyperoxaluria?","volume":"14","author":"Martin-Higueras","year":"2021","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2025.12.029_bib70","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s40620-021-01116-9","article-title":"Treatment with stiripentol in a patient with primary hyperoxaluria type 1: lesson for the clinical nephrologist","volume":"35","author":"Violier","year":"2022","journal-title":"J Nephrol"},{"key":"10.1016\/j.kint.2025.12.029_bib102","unstructured":"Evaluation of the Efficacy and Safety of Stiripentol in Patients 6 Years and Older With Primary Hyperoxaluria Type 1, 2 or 3 (CRYSTAL). ClinicalTrials.gov identifier: NCT06465472. Updated June 18, 2024. Accessed February 4, 2026. https:\/\/clinicaltrials.gov\/study\/NCT06465472"},{"key":"10.1016\/j.kint.2025.12.029_bib71","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1681\/ASN.0000000690","article-title":"Characterization of CHK-336, a first-in-class, liver-targeted, small-molecule lactate dehydrogenase inhibitor for hyperoxaluria treatment","volume":"36","author":"Cox","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.12.029_bib103","unstructured":"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CHK-336 in Healthy Volunteers. ClinicalTrials.gov identifier: NCT05367661. Updated November 3, 2023. Accessed February 4, 2026. https:\/\/clinicaltrials.gov\/study\/NCT05367661"},{"key":"10.1016\/j.kint.2025.12.029_bib72","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1016\/j.juro.2012.12.004","article-title":"Lanthanum carbonate inhibits intestinal oxalate absorption and prevents nephrocalcinosis after oxalate loading in rats","volume":"189","author":"Robijn","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.kint.2025.12.029_bib73","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ekir.2024.11.020","article-title":"A targeted release capsule of lanthanum carbonate: a new efficient cheap treatment for primary hyperoxalurias","volume":"10","author":"De Broe","year":"2025","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2025.12.029_bib74","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/iju5.12296","article-title":"Lanthanum carbonate to control plasma and urinary oxalate level in type 1 primary hyperoxaluria?","volume":"4","author":"Pozdzik","year":"2021","journal-title":"IJU Case Rep"},{"key":"10.1016\/j.kint.2025.12.029_bib75","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfae099","article-title":"Primary hyperoxaluria in adults and children: a nationwide cohort highlights a persistent diagnostic delay","volume":"17","author":"Pszczolinski","year":"2024","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2025.12.029_bib76","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1186\/s12882-025-04460-1","article-title":"Real-world burden of primary hyperoxaluria with chronic kidney disease in the United States: a retrospective administrative claims analysis","volume":"26","author":"Goldfarb","year":"2025","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.kint.2025.12.029_bib77","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1007\/s40620-025-02243-3","article-title":"Primary hyperoxaluria type 1 diagnosis in adult dialysis patients: prediction model assessment in a group of Italian patients","volume":"38","author":"Ferraro","year":"2025","journal-title":"J Nephrol"},{"key":"10.1016\/j.kint.2025.12.029_bib78","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/ndt\/gfad184","article-title":"A clinical screening algorithm for primary hyperoxaluria type 1 in adults on dialysis","volume":"39","author":"Ferraro","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.12.029_bib79","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.kint.2023.01.029","article-title":"Glycolate oxidase inhibition by lumasiran varies between patients with primary hyperoxaluria type 1","volume":"103","author":"Garrelfs","year":"2023","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.12.029_bib80","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1007\/s00467-022-05836-3","article-title":"Three Tesla magnetic resonance imaging detects oxalate osteopathy in patients with primary hyperoxaluria type I","volume":"38","author":"Merz","year":"2023","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2025.12.029_bib81","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ekir.2021.11.020","article-title":"Granulomatous inflammation and hypercalcemia in patients with severe systemic oxalosis","volume":"7","author":"Perrin","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2025.12.029_bib82","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1007\/s00467-019-04330-7","article-title":"Subclinical myocardial disease in patients with primary hyperoxaluria and preserved left ventricular ejection fraction: a two-dimensional speckle-tracking imaging study","volume":"34","author":"Lagies","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2025.12.029_bib83","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1093\/ndt\/gfaf060","article-title":"Controlled access to lumasiran in primary hyperoxaluria type 1: evaluation of a new access route for orphan drugs in The Netherlands","volume":"40","author":"Deesker","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.12.029_bib84","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s13023-025-03738-9","article-title":"Treatment preferences among individuals with primary hyperoxaluria type 1 (PH1): a real-world study","volume":"20","author":"Goldfarb","year":"2025","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.kint.2025.12.029_bib85","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1053\/j.ajkd.2021.09.005","article-title":"End points for clinical trials in hyperoxaluria: case study of patient-focused drug development in a rare disease","volume":"79","author":"Lieske","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2025.12.029_bib86","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2215\/CJN.02810315","article-title":"Predictors of incident ESRD among patients with primary hyperoxaluria presenting prior to kidney failure","volume":"11","author":"Zhao","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.12.029_bib87","first-page":"105","article-title":"The cause of idiopathic calcium stone disease: hypercalciuria or hyperoxaluria?","volume":"26","author":"Robertson","year":"1980","journal-title":"Nephron"},{"key":"10.1016\/j.kint.2025.12.029_bib88","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00467-021-05393-1","article-title":"The effect of lumasiran therapy for primary hyperoxaluria type 1 in small infants","volume":"37","author":"M\u00e9aux","year":"2022","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2025.12.029_bib89","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s40262-025-01540-1","article-title":"Population pharmacokinetic and pharmacodynamic modelling and simulation for nedosiran clinical development and dose guidance in pediatric patients with primary hyperoxaluria type 1","volume":"64","author":"Zhang","year":"2025","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.kint.2025.12.029_bib90","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.kint.2024.08.035","article-title":"Presentation and outcome in carriers of pathogenic variants in SLC34A1 and SLC34A3 encoding sodium-phosphate transporter NPT 2a and 2c","volume":"107","author":"Brunkhorst","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.12.029_bib91","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.ajhg.2022.05.008","article-title":"A spectrum of recessiveness among Mendelian disease variants in UK Biobank","volume":"109","author":"Barton","year":"2022","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.kint.2025.12.029_bib92","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41588-024-01965-7","article-title":"Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits","volume":"57","author":"Scherer","year":"2025","journal-title":"Nat Genet"},{"key":"10.1016\/j.kint.2025.12.029_bib93","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1681\/ASN.2014070698","article-title":"Phenotype-genotype correlations and estimated carrier frequencies of primary hyperoxaluria","volume":"26","author":"Hopp","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.12.029_bib94","doi-asserted-by":"crossref","DOI":"10.1002\/jimd.70052","article-title":"A minor haplotype variant determines the pathogenicity of the p.Ile279Thr substitution in the primary hyperoxaluria type 1 gene, AGXT","volume":"48","author":"Ruta","year":"2025","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.kint.2025.12.029_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2025.101443","article-title":"Data-driven consideration of genetic disorders for global genomic newborn screening programs","volume":"27","author":"Minten","year":"2025","journal-title":"Genet Med"},{"key":"10.1016\/j.kint.2025.12.029_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2024.101077","article-title":"Gene selection for genomic newborn screening: moving toward consensus?","volume":"26","author":"Downie","year":"2024","journal-title":"Genet Med"},{"key":"10.1016\/j.kint.2025.12.029_bib97","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ekir.2024.10.006","article-title":"Effective newborn screening for type 1 and 3 primary hyperoxaluria","volume":"10","author":"Hoppe","year":"2025","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2025.12.029_bib98","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00467-024-06467-6","article-title":"Unveiling atypical diagnoses: when whole-genome analysis performed for refractory infantile hypomagnesemia reveals primary hyperoxaluria","volume":"40","author":"Kayal","year":"2024","journal-title":"Pediatr Nephrol"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826000530?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826000530?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:10:38Z","timestamp":1793049038000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253826000530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":103,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0085253826000530"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2025.12.029","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary hyperoxaluria(s): from trials to real-life data and pipeline therapies","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2025.12.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}